ArticleJournal of cardiac failure2018
Long-Acting Octreotide Reduces the Recurrence of Gastrointestinal Bleeding in Patients With a Continuous-Flow Left Ventricular Assist Device.
Article in Journal of cardiac failure, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 37 citations in OpenAlex.
- Octreotide therapy in patients with a left ventricular assist device and bleeding gastrointestinal angiodysplasias.The American journal of the medical sciences · 2025Article
- Review
- Gastrointestinal bleeding on continuous-flow left ventricular assist device therapy.ESC heart failure · 2023Review
- Review
- Left Ventricular Assist Devices: A Primer For the General Cardiologist.Journal of the American Heart Association · 2022Review
- Role of octreotide in small bowel bleeding.World journal of clinical cases · 2022Review
- Prevalence, management, and outcomes of haemorrhagic events in left ventricular assist device recipients.ESC heart failure · 2022Article
- The History of Durable Left Ventricular Assist Devices and Comparison of Outcomes: HeartWare, HeartMate II, HeartMate 3, and the Future of Mechanical Circulatory Support.Journal of clinical medicine · 2022Review
- Article
- Implication of Hemodynamic Assessment during Durable Left Ventricular Assist Device Support.Medicina (Kaunas, Lithuania) · 2020Review
- Treatment of gastrointestinal bleeding in left ventricular assist devices: A comprehensive review.World journal of gastroenterology · 2020Review
- Resource utilization and hospital readmission associated with gastrointestinal bleeding in patients with continuous-flow left ventricular assist devices.Journal of thrombosis and thrombolysis · 2019Article
- Omega-3 Therapy Is Associated With Reduced Gastrointestinal Bleeding in Patients With Continuous-Flow Left Ventricular Assist Device.Circulation. Heart failure · 2018Article
- Initial endoscopic intervention is not associated with reduced risk of recurrent gastrointestinal bleeding in left ventricular assist device patients.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundRecurrent gastrointestinal bleeding is one of the most significant adverse events in patients with left ventricular assist devices (LVADs).
methodsWe enrolled LVAD patients who had received an intramuscular injection of 20 mg octreotide every 4 weeks as secondary prevention for recurrent gastrointestinal bleeding despite conventional medical therapies and repeated transfusions. The frequency of gastrointestinal bleeding and other associated clinical outcomes before and during octreotide therapy were compared.
resultsThirty LVAD patients (66.4 ± 8.8 years old, 16 men [53%]) received octreotide therapy for 498.8 ± 356.0 days without any octreotide-associated adverse events. The frequency of gastrointestinal bleeding was decreased significantly during octreotide therapy (from 3.4 ± 3.1 to 0.7 ± 1.3 events/year; P < .001), accompanied by significant reductions in red blood cell and flesh frozen plasma transfusions, days in hospital, and need for endoscopic procedures (P < .05 for all).
conclusionsOctreotide therapy reduced the frequency of recurrent gastrointestinal bleeding and may be considered for secondary prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.